Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children

Pediatric Infectious Disease Journal

Volumn 34, Issue 8, 2015, Pages 851-857

  Himes, Sarah K ^a   Wu, Julia W ^b   Jacobson, Denise L ^c   Tassiopoulos, Katherine ^b   Hazra, Rohan ^d   Kacanek, Deborah ^c   Van Dyke, Russell B ^e   Rich, Kenneth C ^f   Siberry, George K ^d   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antiretroviral; birth; bone; DXA; growth; HIV exposed uninfected children; meconium; tenofovir

Indexed keywords

TENOFOVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BIRTH WEIGHT; BODY HEIGHT; BONE MINERAL; CHILD GROWTH; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MATERNAL PLASMA; MECONIUM; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ADOLESCENT; ADULT; BONE DENSITY; CHEMISTRY; DRUG EFFECTS; HIV INFECTIONS; MATERNAL EXPOSURE; MIDDLE AGED; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VERTICAL TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BONE DENSITY; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MATERNAL EXPOSURE; MECONIUM; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TENOFOVIR; YOUNG ADULT;

EID: 84937405927     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000747     Document Type: Article

References (51)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Updated May 2014). Department of Health and Human Services. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 11, 2014
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (Updated March 2014). Department of Health and Human Services. Available from: http://aidsinfo.nih. gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed March 28, 2014
3. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012; 26: 1151-1159
4. Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 2002; 29: 207-220
5. Tarantal AF, Marthas ML, Shaw JP, et al. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20: 323-333
6. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008; 52: 3144-3160
7. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011; 2011: 354908
8. Hall AM. Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2013; 28: 1011-1023
9. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013; 32: 495-500
10. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-Associated renal and bone toxicity. HIV Med. 2009; 10: 482-487
11. Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2012; 7: e38377
12. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012; 7: e32445
13. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008; 152: 582-584
14. Gafni RI, Hazra R, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics. 2006; 118: E711-E718
15. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIVnegative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011; 6: e23688
16. Hirt D, Urien S, Ekouevi DK, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009; 85: 182-189
17. Neumanova Z, Cerveny L, Ceckova M, et al. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014; 28: 9-17
18. Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr. 2013; 64: 374-381
19. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-Term ART with and without tenofovir in the DART trial. PLoS Med. 2012; 9: e001217
20. Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther. 2011; 16: 1259-1266
21. Siberry, G. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. Oral abstract: Critical issues in MTCT: Maternal health, and HIV treatment in children. Presented at the Conference on Retroviruses and Opportunistic Infections, March 5, 2014. Boston, MA. Available from: http://www.croiwebcasts.org/portal; jsessionid=0C699575B FA7F6350D4BE9C223473F34. Accessed April 1, 2015
22. Wang L, Kourtis AP, Ellington S, et al. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis. 2013; 57: 1773-1781
23. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007; 388: 1455-1465
24. Ostrea EM Jr, Romero A, Knapp DK, et al. Postmortem drug analysis of meconium in early-gestation human fetuses exposed to cocaine: clinical implications. J Pediatr. 1994; 124: 477-479
25. Gray TR, Eiden RD, Leonard KE, et al. Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. Nicotine Tob Res. 2010; 12: 658-664
26. Gray TR, Choo RE, Concheiro M, et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction. 2010; 105: 2151-2159
27. Himes SK, Stroud LR, Scheidweiler KB, et al. Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes. J Pediatr. 2013; 162: 970-975
28. Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008; 84: 604-612
29. Himes SK, Scheidweiler KB, Tassiopoulos K, et al. Development and validation of the first liquid chromatography-Tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium. Anal Chem. 2013; 85: 1896-1904
30. DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. AIDS. 2013; 27: 211-220
31. Burd L, Hofer R. Biomarkers for detection of prenatal alcohol exposure: a critical review of fatty acid ethyl esters in meconium. Birth Defects Res A Clin Mol Teratol. 2008; 82: 487-493
32. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for- Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: World Health Organization; 2006
33. WHO Multicentre Growth Reference Study Group, De Onis M. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl. 2006; 450: 76-85
34. Tassiopoulos K, Read JS, Brogly S, et al. Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010; 14: 1269-1278
35. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach; June 2013. Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed March 28, 2014
36. Hirnschall G, Harries AD, Easterbrook PJ, et al. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013; 16: 18757
37. Harvey NC, Mahon PA, Robinson SM, et al. Different indices of fetal growth predict bone size and volumetric density at 4 years of age. J Bone Miner Res. 2010; 25: 920-927
38. Gallo S, Vanstone CA, Weiler HA. Normative data for bone mass in healthy term infants from birth to 1 year of age. J Osteoporos. 2012; 2012: 672403
39. Williams PL, Seage GR 3rd, Van Dyke RB, et al. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol. 2012; 175: 950-961
40. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1- infected pregnant women and their infants. Antimicrob Agents Chemother. 2011; 55: 5914-5922
41. Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014; 65: 33-41
42. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-Associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007; 71: 619-627
43. Nirogi R, Bhyrapuneni G, Kandikere V, et al. Pharmacokinetic profiling of efavirenz-emtricitabine-Tenofovir fixed dose combination in pregnant and non-pregnant rats. Biopharm Drug Dispos. 2012; 33: 265-277
44. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999; 5: 1048-1051
45. Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci. 2009; 98: 2317-2335
46. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006; 42: 441-449
47. Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006; 50: 2471-2477
48. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006; 43: 278-283
49. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-Associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis. 2008; 197: 102-108
50. Reynolds LP, Redmer DA. Utero-placental vascular development and placental function. J Anim Sci. 1995; 73: 1839-1851
51. Reynolds LP, Caton JS, Redmer DA, et al. Evidence for altered placental blood flow and vascularity in compromised pregnancies. J Physiol. 2006; 572(Pt 1): 51-58